251 related articles for article (PubMed ID: 25965947)
41. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Lakshmanan I; Ponnusamy MP; Das S; Chakraborty S; Haridas D; Mukhopadhyay P; Lele SM; Batra SK
Oncogene; 2012 Feb; 31(7):805-17. PubMed ID: 21785467
[TBL] [Abstract][Full Text] [Related]
42. Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents.
Rao TD; Xu M; Eng S; Yang G; Manson R; Rosales N; Kumar R; Veillard IE; Zhou Q; Iasonos A; Ouerfelli O; Djaballah H; Spriggs DR; Yeku OO
Mol Cancer Ther; 2022 May; 21(5):775-785. PubMed ID: 35413118
[TBL] [Abstract][Full Text] [Related]
43. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
McLemore MR; Aouizerat B
Biol Res Nurs; 2005 Apr; 6(4):262-7. PubMed ID: 15788735
[TBL] [Abstract][Full Text] [Related]
44. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
Das S; Rachagani S; Torres-Gonzalez MP; Lakshmanan I; Majhi PD; Smith LM; Wagner KU; Batra SK
Oncotarget; 2015 Mar; 6(8):5772-87. PubMed ID: 25691062
[TBL] [Abstract][Full Text] [Related]
45. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
[TBL] [Abstract][Full Text] [Related]
46. Pathobiological implications of MUC16 expression in pancreatic cancer.
Haridas D; Chakraborty S; Ponnusamy MP; Lakshmanan I; Rachagani S; Cruz E; Kumar S; Das S; Lele SM; Anderson JM; Wittel UA; Hollingsworth MA; Batra SK
PLoS One; 2011; 6(10):e26839. PubMed ID: 22066010
[TBL] [Abstract][Full Text] [Related]
47. MUC16/CA125 in the context of modular proteins with an annotated role in adhesion-related processes: in silico analysis.
Jankovic M; Mitic N
Int J Mol Sci; 2012; 13(8):10387-10400. PubMed ID: 22949868
[TBL] [Abstract][Full Text] [Related]
48. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells.
Lei Y; Zang R; Lu Z; Zhang G; Huang J; Liu C; Wang Z; Mao S; Che Y; Wang X; Zheng S; Fang L; Sun N; He J
Cell Death Dis; 2020 Oct; 11(10):853. PubMed ID: 33056994
[TBL] [Abstract][Full Text] [Related]
49. Mucins and Truncated
Coelho R; Marcos-Silva L; Mendes N; Pereira D; Brito C; Jacob F; Steentoft C; Mandel U; Clausen H; David L; Ricardo S
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011875
[TBL] [Abstract][Full Text] [Related]
50. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
51. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
52. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
53. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
[TBL] [Abstract][Full Text] [Related]
54. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract][Full Text] [Related]
55. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
56. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
57. Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
White B; Patterson M; Karnwal S; Brooks CL
Proteins; 2022 May; 90(5):1210-1218. PubMed ID: 35037700
[TBL] [Abstract][Full Text] [Related]
58. [Tumor Marker CA125: biochemical and molecular properties].
Bouanène H; Miled A
Bull Cancer; 2009 May; 96(5):597-601. PubMed ID: 19435686
[TBL] [Abstract][Full Text] [Related]
59. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
60. MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.
Shen H; Guo M; Wang L; Cui X
Genes Genomics; 2020 Feb; 42(2):127-133. PubMed ID: 31736008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]